TargetMol

Dichloromethotrexate

Product Code:
 
TAR-T25324
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T25324-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25324-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25324-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Dichloromethotrexate is an enzyme dihydrofolate reductase inhibitor, thus preventing the synthesis of purine nucleotides and thymidylates and inhibiting DNA and RNA synthesis. This agent is metabolized and excreted by the liver.
CAS:
528-74-5
Formula:
C20H20Cl2N8O5
Molecular Weight:
523.33
Purity:
0.98
SMILES:
CN(Cc1cnc2nc(N)nc(N)c2n1)c1c(Cl)cc(cc1Cl)C(=O)N[C@@H](CCC(O)=O)C(O)=O

References

1. Meyers FJ, Blumenstein B, Crawford ED, Hynes HE, Montie JE, Taylor SA, Grossman HB, Natale RB. Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study. J Urol. 1992 Jul;148(1):52-4. PubMed PMID: 1613880. 2. Wampler GL, Ahlgren JD, Lokich JJ, Gullo JJ, Phillips JA. Dichloromethotrexate, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small cell lung cancer. A MAOP study. Am J Clin Oncol. 1991 Oct;14(5):442-5. PubMed PMID: 1659178. 3. Rosowsky A, Wright JE, Holden SA, Waxman DJ. Influence of lipophilicity and carboxyl group content on the rate of hydroxylation of methotrexate derivatives by aldehyde oxidase. Biochem Pharmacol. 1990 Aug 15;40(4):851-7. PubMed PMID: 1696821. 4. Bertino JR. Pharmacology of dichloromethotrexate. J Natl Cancer Inst. 1989 May 10;81(10):815-6. PubMed PMID: 2716075.